Study shows proof of concept of BioIVT HEPATOPAC cultures with targeted assay to evaluate bioactivation potential and drug-induced liver injury (DILI) risk

October 12, 2020

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).1

DILI contributes to the high failure rate of drug candidates in clinical development; but frequently DILI risk is not evident until late in clinical trials. There remains a need for better preclinical models to screen drug candidates for DILI risk during the lead selection and optimization process.

The in vitro Bioactivation Liver Response Assay (BA-LRA) is a method based on a set of liver gene expression biomarkers that respond quantitatively to chemically reactive metabolites that are predicted to trigger bioactivation-mediated clinical DILI.

BioIVT's HEPATOPAC model was selected for the in vitro BA-LRA because of its long-term viability and demonstrated in-vivo relevance. The HEPATOPAC model is an in vitro bioengineered co-culture of primary hepatocytes and fibroblasts, which is used extensively for liver-based safety, metabolism, and efficacy evaluations of small molecule drug candidates.

The work, conducted by scientists at Merck Research Laboratories and published in the peer reviewed journal Toxicological Sciences, describes application of the in vitro BA-LRA using the HEPATOPAC model to evaluate 93 compounds known to be DILI positive or negative in humans. The assay was able to differentiate the drugs with lower DILI risk with an 81% sensitivity and 90% specificity in the rat HEPATOPAC model and a 68% sensitivity and 86% specificity in the human HEPATOPAC model.

"The high in-vitroin-vivo correlation of HEPATOPAC cultures, combined with their long-term viability makes this an excellent system for novel ADME Tox and disease models. This publication adds to the body of evidence for the utility of these assays as early de-risking tools to reduce the risk of drug induced liver injury in pharmaceutical development," said BioIVT Senior VP ADME Dr. Christopher Black.
-end-
Dr. Wen Kang, Merck Research Laboratories, is scheduled to present these study results and answer questions during BioIVT's Virtual HEPATOPAC User Group Meeting on Oct. 22. Interested persons can https://info.bioivt.com/hugm-reg-lp?hsCtaTracking=aeaf8487-9d05-4c23-aa2f-034b85135dc1%7Cf1193546-b7f6-43a1-a1b7-60acd60d6857.

Reference

1. Kang W, Podtelezhnikov AA, Tanis KQ, Pacchione S, Su M, Bleicher KB, Wang Z, Laws GM, Griffiths TG, Kuhls MC, Chen Q, Knemeyer I, Marsh DJ, Mitra K, Lebron J, and Sistare FD. Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline. 19 June 2020. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfaa094

About BioIVT

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit http://www.bioivt.com or follow the company on Twitter @BioIVT.

Rana Healthcare Solutions LLC

Related Drug Candidates Articles from Brightsurf:

Researcher found female candidates are more likely to discuss the economy than males
In a new study published in Politics & Policy, Deserai Crow, PhD, associate professor at the University of Colorado Denver in the School of Public Affairs, found significant differences in discussion topics between both party affiliation and gender.

Candidates who lie more likely to win elections - new study
A new economics experiment suggests the electoral system attracts candidates who are dishonest and highlights why greater transparency might foster more trust in politics.

Scientists identify promising new ALS drug candidates
Scientists have taken a significant step forward in the search to find effective new drug candidates for the treatment of Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease.

When it comes to supporting candidates, ideology trumps race and gender
Voters who express prejudice against minorities and women are still more likely to support candidates who most closely align with their ideologies, regardless of the race or sex of such candidates, according to research published by the American Psychological Association.

Scientists identify hundreds of drug candidates to treat COVID-19
Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.

Cell 'membrane on a chip' could speed up screening of drug candidates for COVID-19
Researchers have developed a human cell 'membrane on a chip' that allows continuous monitoring of how drugs and infectious agents interact with our cells, and may soon be used to test potential drug candidates for COVID-19.

Candidates who use humor on Twitter may find the joke is on them
Political candidates' use of humor on social media could sometimes backfire on them with potential supporters, new research suggests.

Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease
A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (Mpro) and one of them is a good drug candidate for further clinical studies.

Essential oil components can be tested as drug candidates
A research team at the VIB-KU Leuven Center for Microbiology and the KU Leuven Department of Biology showed that, contrary to generally held belief, most components of essential oils could meet the criteria set for drug candidates.

Alzheimer's drug candidates reverse broader aging, study shows
In mouse models of Alzheimer's disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells.

Read More: Drug Candidates News and Drug Candidates Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.